vTv Therapeutics Inc (NASDAQ:VTVT) Major Shareholder Acquires $196,500.00 in Stock
vTv Therapeutics Inc (NASDAQ:VTVT) major shareholder Ronald O. Perelman purchased 150,000 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The shares were acquired at an average price of $1.31 per share, with a total value of $196,500.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
VTVT stock opened at $1.39 on Thursday. vTv Therapeutics Inc has a one year low of $0.68 and a one year high of $6.09. The stock has a market capitalization of $71.43 million, a PE ratio of -2.01 and a beta of -3.71. The company has a fifty day moving average of $1.37 and a 200-day moving average of $1.68.
vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Wednesday, July 31st. The biotechnology company reported ($0.09) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.02. The firm had revenue of $1.83 million during the quarter, compared to analyst estimates of $1.63 million. Equities research analysts forecast that vTv Therapeutics Inc will post -0.53 earnings per share for the current year.
An institutional investor recently bought a new position in vTv Therapeutics stock. Wedbush Securities Inc. bought a new position in vTv Therapeutics Inc (NASDAQ:VTVT) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 17,500 shares of the biotechnology company’s stock, valued at approximately $30,000. Institutional investors own 3.71% of the company’s stock.
vTv Therapeutics Company Profile
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.
Further Reading: Cost of Capital Explained
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.